Naptumomab estafenatox

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameNaptumomab estafenatox
Drug Alias Name他那莫单抗naptumomab estafenatoxnaptumomabum estafenatoxum埃托-那普妥莫单抗Anyara +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT lymphocytes stimulantsTrophoblast glycoprotein modulators
TargetsTrophoblast glycoprotein
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsUterine Cervical Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesActive Biotech Ab
China Registration ClassN/A

Develop Information

Active CompaniesNeotx Therapeutics Ltd
Inactive CompaniesWeill Medical College of Cornell UniversityActive Biotech Ab
Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsUterine Cervical Neoplasms +[18] 
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksWikipedia